Davide Isaia

Davide Isaia has a diverse work experience spanning from 2014 to present. From 2014 to 2016, they were an intern at the Università degli Studi di Milano-Bicocca, where they worked in the Laboratory of Biochemistry to determine the glycolytic efficiency and mitochondrial respiratory capacity of a 5-Fluorouracil (5-FU) sensitive and resistant human colon adenocarcinoma cell line using Seahorse XF Technology. From 2016 to 2018, they worked at FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA as an MSc Internship - Laboratory of molecular and cellular Immunopathology, where they tested in vitro the effect of the hypoxia-inducible factor modulator FM19G11 on proliferation and self-renewal of primary ependymal Neural Stem Cells derived from G93A-SOD1 mice (ALS mouse model) compared to B6. SJL mice (control). Since 2018, Davide has been employed at Skyhawk Therapeutics as a Research Associate I and II, where they work in the research and development of novel therapeutics.

Davide Isaia has an extensive educational background. Davide obtained a Scientific secondary school diploma from Liceo Scientifico "P. Ruggieri" (Marsala) in 2010. In 2009, they completed the ECDL Core Full Certificate at the ECDL Foundation. Davide also obtained the First Certificate in English (FCE) Livello B2 in June 2010. From 2010 to 2014, they completed a Bachelor's degree in Biotecnology at Università degli Studi di Milano-Bicocca. Davide then completed a Master's degree in Biology at the same university from 2014 to 2017. In 2009, they also attended Maria Carrillo High School in Santa Rosa, California.